SlideShare ist ein Scribd-Unternehmen logo
1 von 38
FROM HUMAN GENOME PROJECT TO HUMAN PROTEOME PROJECT /HPP/: RUSSIAN PARTICIPATION ARCHAKOV A.I. INSTITUTE OF BIOMEDICAL CHEMISTRY   OF RAMS, MOSCOW, RUSSIA www.ibmc.msk.ru [ HTTP://WWW.PROTEOME.RU/EN/ROADMAP ]
GENOME [OUTLINE] TRANSCRIPTOME [LAYOUT] PROTEOME   [PRODUCT]
THE MAIN DIFFERENCE BETWEEN  GENOMICS AND PROTEOMICS: THE SAME GENOME THE DIFFERENT PROTEOME CATERPILLAR BUTTERFLY
STEPS OF HPP HUPO FORMATION:  BARBADOS  CONFERENCE 2007  05/11-01-2007  H.   PEARSEN. BIOLOGISTS INITIATE PLAN TO MAP HUMAN PROTEOME.  NATURE, 452, 24,  920-921,  2008. HUMAN PROTEOME PROJECT HUPO 2008, 7 th  WORLD   CONGRESS, 16/20-08-08,Amsterdam, NL   HPP MOSCOW WORKSHOP, RUSSIA 20/21-03,2009 SEOUL ,  KHUPO ,  26/27-03-2009 CANADIAN   HUPO ,  TORONTO, 26/ 30 -0 9 -2009
[object Object],[object Object],[object Object]
HOW MANY PROTEINS EXIST IN HUMAN BODY? 22  PAIRS SOMATIC CHR 1 PAIR SEX CHR ________________________________________________ [1]  The sequence of the human genome. Venter et al., Science. 2001 [2]  Extent of modifications in Human Proteome Samples…, Nielsen et al., MCP, 2009 [3]  Biospecific irreversible fishing… Archakov  et al.,  Proteomics , 2009   HUMAN GENOME 20 000  GENES [1] ~ 5 0  PROTEIN FORMS PER GENE [2] ~ 1 [2]  - 2 [3]  MLN.PROTEINS
HOW MANY PROTEINS IN HUMAN PROTEOME :  dependence between detection limit of the staining method and number of proteins spots  on 2DE. (Archakov et al., PROTEOMICS (2009),  9, 1326-1343).  DL , М 10 - 6 10 - 9 10 - 8 10 - 7 10 -20 10 -24 10 100 1000 500 2000 380   Thsnd Silver Tio Silver Glutar Cy5 Cy5Sat AmidoBlack Number of   protein species Coummassi Blue HEP G2 CELLS BLOOD PLASMA Staining Methods: 2.2 Mln 10 - 10 10 -1 1 10 -1 2 10 -1 3 3000 4000 5000
 
 
WHY GENE CENTRIC  PROTEOME PROJECT IS REALISTIC? ,[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
CHROMOSOME STATISTICS Ensembl release 60 - Nov 2010  http://www.ensembl.org LENGTH (BPS): 78,077,248 GENES 513 KNOWN PROTEIN-CODING GENES: 285 PSEUDOGENE GENES: 64 miRNA Genes: 32 rRNA Genes: 13 snRNA Genes: 51 snoRNA Genes: 36 Misc RNA Genes: 25
DATA   MINING STATISTICS FOR 18 th  CHROMOSOME: 286   MASTER  PROTEIN   CODING GENES PRIDE  = 224 identified proteins Protein Atlas  = 102 proteins  In PRIDE only In PRIDE and in Protein Atlas In Protein Atlas only 48  PROTEINS – NOT CONFIRMED ( 1 2) (13 4 ) (90)
How many proteins can we expect for 18 th  chromosome ?  28 5   Trancriptome analisys of 18 th  chromosome Over 80% of the genes undergo alternative splicing  (Kampa at. al,  Genome Res., 2004, 14, 331-342)  + 230 516  On average, each of them can have 50 PTMs (Nielsen M, Savitski M, Zubarev R, MCP, 2006, 5, 2384-) x 50 25800 Protein species can be expected as expressed  in HepG2 cell line
http://www.proteome.ru/en/roadmap/  http://www.hupo.org/research/hpp/soc/ ROADMAP PROTEOME  OF THE 18-TH HUMAN CHROMOSOME: GENE CENTRIC IDENTIFICATION OF TRANSCRIPTS, PROTEINS AND PEPTIDES
RusHPP CONSISTS OF TWO PHASES: GOAL OF THE  PILOT PHASE IS IDENTIFICATION OF  ALL MASTER  PROTEINS  PRODUCED BY 18thCHR  IN LIVER AND HEP2G CELLS AND IDENTIFICATION OF THEM IN PLASMA WITH SENSITIVITY  10 -18  M ( 1   PROTEIN COPY/µL  )  AND  1 PROTEIN COPY PER 10 3  LIVER  OR HEP2G CELLS.
MAIN PHASE OF RusHPP ,[object Object],[object Object],[object Object]
PRINCIPLE DIFFERENCE  BETWEEN GENOMIC AND PROTEOMICS PRINCIPLE DIFFERENCE BETWEEN GENOMIC AND PROTEOMICS IS EXISTENCE  OF POLYMERASE CHAIN REACTION (PCR) IN GENOMICS ALLOWING TO MULTIPLY  NUCLEIC ACID MOLECULES AND ABSENCE OF PCR-LIKE REACTION IN PROTEOMICS. DUE TO PCR  GENOMICS DOES NOT HAVE  DETECTION LIMIT (DL )   OBSTACLE. PROTEOMICS HAS IT.
THREE BOTTLENECKS OF HPP ,[object Object],[object Object],[object Object],LOW SENSITIVITY OF RECENT PROTEOMIC TECHNOLOGIES. THE BEST ONE MRM-MS REACHES SENSITIVITY UP TO 10 -14  M*, CORRESPONDING TO 10 000 PROTEIN COPIES
WHAT IS REVERSE AVOGADRO’s NUMBER ? N A = 6.022x10 23  MOLECULES/MOLE   1 MOLE  -  1L  -  1M   1/N A ≈10 -24  MOLE/MOLECULE  ≈1MOLECULE/L = 10 -24  M [Archakov A.I. et. al.  PROTEOMICS 2007, 7, 4–9 ]
[object Object],[object Object],[object Object]
COMBINING OF IRREVERSIBLE FISHING TECHNOLOGY WITH AFM
CONCENTRATION OF PROTEINS FROM SOLUTION ON THE  ACTIVATED  AFM –CHIP USING IRREVERSIBLE FISHING FISHING -  CONCENTRATION OF PROTEINS IN THE SOLUTION – 10 -11  M ,[object Object],SURFACED CONCENTRATION OF FISHED PROTEINS  – 10 -3  M ,[object Object],[object Object],SOLUTION AFM SURFACE AFM SURFACE AFM IRREVERSIBLE FISHING INCREASES SURFACE CONCENTRATION BY FACTOR OF 10 8
EXPERIMENT SUCCINIMIDE MODIFIED MICA С AVIDIN =10 -13 M ; V=1 ml; T=37 0 C; t  INCUB = 60 min S ACTIVATION =0,4 mm 2 ; S scan =16FRAMES*25  m 2 =4*10 -4  mm 2 t SCAN =240min N MOLECULES =5122  500 molecules /400   m 2 AFM IRREVERSIBLE CHEMICAL FISHING C VS  =5 *10 - 6 M (FROM EXPERIMENT) C VS = 10 - 5 M (FROM THEORY) AVIDIN ON AFM-SUPPORT 5nm 5µm 0
THE DEPENDENCE OF ANTI-HCVcore im  /HCVcoreAg PROTEIN COMPLEX NUMBER ON  HCVcoreAg CONCENTRATION   IN SOLUTION (IRREVERSIBLE BINDING) (ARCHAKOV et al 2009, 9, 1363-1343) EXPERIMENTAL  CONDITIONS : anti-HCVcoreAg imm  ( PHOTO-CROSS LINKER MODIFIED)  SIMS=0,4 mm 2 ; Scan=16 FRAMES *25  m 2 = 4*10 -4   mm 2 t SCAN =240min T = 37 0 C; t = 60 min; ,[object Object],- V=50 mL 10 -17 10 -19 10 -15 10 -13 10 10 2 10 3 10 4 CONCENTRATION, M NUMBER OF COMPLEXES cutoff line 1 – EXPERIMENTAL IRREVERSIBLE BINDING 2 – THEORETICAL IRREVERSIBLE BINDING
COMBINING OF IRREVERSIBLE FISHING WITH MRM MS
Experimental workflow for low and ultra low copied protein detection  QqQ dynamic MRM analysis of individual proteins and in Human Plasma Step 1  Step 2  Step 3 HPLC-Chip Q-TOF (Agilent 6510) HPLC-Chip QqQ  (Agilent 6410)
MRM STRATEGY FOR LOW AND ULTRA-LOW COPIED PROTEIN DETECTION   (BSA and CYP102/BM3/ as an example) Detection limit for purified proteins is 10 -16  M,  600 copies/1   l  (s/n>7)  Detection limit for CYP102 in the  presence of human serum is 10 -14  M  60   000 copies/1   l (s/n>7)  +serum  + trypsin + trypsin
IRREVERSIBLE BINDING OF PROTEINS  ON BrCN-SEPHAROSE BEADS  0.5-50 ml PURIFIED CYP102/BSA IN THE PRESENCE OF HUMAN SERUM IRREVERSIBLE BINDING OF PROTEINS ON BrCN-SEPHAROSE BEADS FOLLOWING  BY DIGESTION WITH TRYPSIN DETECTION LIMIT FOR CYP102/BSA FOR PURIFIED PROTEIN  AND PROTEINS IN  THE PRESENCE OF HUMAN SERUM IS 10 -18  M,  1 COPY/1µL 10E-9M 10E-12M 10E-15M 10E-18M
NEW TECHNOLOGIES FOR Rus-HPP  ,[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],WHAT IT MEANS PROTEOME-BASED MEDICINE?
DETECTION OF HCVcoreAg AT TWO SPOTS AFM CHIP FROM HCVcoreAg SOLUTION (C=10 -9   М ) ANTI-HBsAg imm  (CONTROL SPOT) 1 2 3 4 1 – ANTI HCVcoreAg 2 –  anti-HCVcore imm /HCVcoreAg h=  3-7 nm 3 – ANTI-HBsAg imm 4  –  AFM CHIP AFTER INCUBATION IN   HCVcore Ag (C=10 -9 М ) SOLUTION SURFACE TOPOGRAPHY HAS NOT CHANGED ANTI-HCVcoreAg imm  SPOT
HCVcoreAg HBsAg COINCIDENCE  – 76% COINCIDENCE  – 8 9 % COMPARISON OF AFM AND OTHER METHODS (ELISA AND PCR)  FOR DETECTION OF HBsAg AND HCVcoreAg 132 aa of 191 (70%) in  HCVcore  PROTEIN SEQUENCE ARE INVARIANT [Bukh et.al., PNAS, 1994, 91, 8239-8234 ]  POSSIBLE REASON OF DISAGREEMENT : 183 aa of 226 (80%) in  HBsAg  PROTEIN SEQUENCE ARE INVARIANT  [Norder et.al., J. Gener. Virol.,, 1992, 73, 1201-1208 ]  PCR (RNA HCV) А FM + - + 24 2 - 8 7 ELISA AFM + - + 25 3 - 1 6
PROTEOTYPE IS A RESULT OF: NEW DIAGNOSTIC TESTS BASED ON PROTEOTYPING
[object Object],[object Object],[object Object],[object Object],[object Object],WHAT IT MEANS PROTEOME-BASED MEDICINE/continuation/?
(A) AFM IMAGES OF PHOSPHOLIPID NANOPARTICLES ON THE MICA SURFACE (A)  AND  DISTRIBUTION OF PARTICLES BY SIZE  (B) (B)
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Weitere ähnliche Inhalte

Was ist angesagt?

Reeta yadav. roll no. 02. transposable element in eukaryotes.
Reeta yadav. roll no. 02. transposable element in eukaryotes.Reeta yadav. roll no. 02. transposable element in eukaryotes.
Reeta yadav. roll no. 02. transposable element in eukaryotes.
Manisha Jangra
 
Expression systems
Expression systemsExpression systems
Expression systems
ankit
 
Directed Evolution
Directed EvolutionDirected Evolution
Directed Evolution
Ifrah Ishaq
 
Directed evolution
Directed evolutionDirected evolution
Directed evolution
Ifrah Ishaq
 

Was ist angesagt? (20)

Reeta yadav. roll no. 02. transposable element in eukaryotes.
Reeta yadav. roll no. 02. transposable element in eukaryotes.Reeta yadav. roll no. 02. transposable element in eukaryotes.
Reeta yadav. roll no. 02. transposable element in eukaryotes.
 
Expression systems
Expression systemsExpression systems
Expression systems
 
Map based cloning of genome
Map based cloning of genomeMap based cloning of genome
Map based cloning of genome
 
Expression systems
Expression systemsExpression systems
Expression systems
 
Directed Evolution
Directed EvolutionDirected Evolution
Directed Evolution
 
Yeast two hybrid system for Protein Protein Interaction Studies
Yeast two hybrid system for Protein Protein Interaction StudiesYeast two hybrid system for Protein Protein Interaction Studies
Yeast two hybrid system for Protein Protein Interaction Studies
 
S1 Mapping
S1 Mapping  S1 Mapping
S1 Mapping
 
cohesive and blunt end ligation
cohesive and blunt end ligationcohesive and blunt end ligation
cohesive and blunt end ligation
 
Protein dna interactions
Protein dna interactionsProtein dna interactions
Protein dna interactions
 
Global and local alignment (bioinformatics)
Global and local alignment (bioinformatics)Global and local alignment (bioinformatics)
Global and local alignment (bioinformatics)
 
DNA protein interaction.pptx
DNA protein interaction.pptxDNA protein interaction.pptx
DNA protein interaction.pptx
 
Histidine Operon
Histidine OperonHistidine Operon
Histidine Operon
 
Mapping and quantifying transcripts.pdf
Mapping and quantifying transcripts.pdfMapping and quantifying transcripts.pdf
Mapping and quantifying transcripts.pdf
 
Protein protein interactions
Protein protein interactionsProtein protein interactions
Protein protein interactions
 
Directed evolution
Directed evolutionDirected evolution
Directed evolution
 
Reverse transcription-quantitative PCR (RT-qPCR): Reporting and minimizing th...
Reverse transcription-quantitative PCR (RT-qPCR): Reporting and minimizing th...Reverse transcription-quantitative PCR (RT-qPCR): Reporting and minimizing th...
Reverse transcription-quantitative PCR (RT-qPCR): Reporting and minimizing th...
 
Gene prediction and expression
Gene prediction and expressionGene prediction and expression
Gene prediction and expression
 
Protein protein interaction
Protein protein interactionProtein protein interaction
Protein protein interaction
 
ChIP-seq Theory
ChIP-seq TheoryChIP-seq Theory
ChIP-seq Theory
 
Site directed mutagenesis
Site  directed mutagenesisSite  directed mutagenesis
Site directed mutagenesis
 

Ähnlich wie Archakov A. from human genome project to human proteome project

RNA Extraction of Peste Des Petits Ruminants Virus (PPRV) from Clinical Sampl...
RNA Extraction of Peste Des Petits Ruminants Virus (PPRV) from Clinical Sampl...RNA Extraction of Peste Des Petits Ruminants Virus (PPRV) from Clinical Sampl...
RNA Extraction of Peste Des Petits Ruminants Virus (PPRV) from Clinical Sampl...
ZULKIFAL HUSSAIN
 
PRODUCTION OF SEROTYPE 6-DERIVED RECOMBINANT ADENO-ASSOCIATED VIRUS IN SERUM-...
PRODUCTION OF SEROTYPE 6-DERIVED RECOMBINANT ADENO-ASSOCIATED VIRUS IN SERUM-...PRODUCTION OF SEROTYPE 6-DERIVED RECOMBINANT ADENO-ASSOCIATED VIRUS IN SERUM-...
PRODUCTION OF SEROTYPE 6-DERIVED RECOMBINANT ADENO-ASSOCIATED VIRUS IN SERUM-...
Dr. Érica Schulze
 
6-8-2015 AACC Poster HIV p24 S-PLEX - Stengelin_final
6-8-2015 AACC Poster HIV p24 S-PLEX - Stengelin_final6-8-2015 AACC Poster HIV p24 S-PLEX - Stengelin_final
6-8-2015 AACC Poster HIV p24 S-PLEX - Stengelin_final
Lawrence Hwang
 
A visual chip-based coimmunoprecipitation technique for analysis of protein–p...
A visual chip-based coimmunoprecipitation technique for analysis of protein–p...A visual chip-based coimmunoprecipitation technique for analysis of protein–p...
A visual chip-based coimmunoprecipitation technique for analysis of protein–p...
Qing Chen
 
Implementation of histopathological techniques and transmission electron micr...
Implementation of histopathological techniques and transmission electron micr...Implementation of histopathological techniques and transmission electron micr...
Implementation of histopathological techniques and transmission electron micr...
Agriculture Journal IJOEAR
 
Pcr array whitepaper_app
Pcr array whitepaper_appPcr array whitepaper_app
Pcr array whitepaper_app
Elsa von Licy
 
Microarray validation
Microarray validationMicroarray validation
Microarray validation
Elsa von Licy
 

Ähnlich wie Archakov A. from human genome project to human proteome project (20)

Molecular diagnosis of Mycobacterium tuberculosis TB - Second MBBS -
Molecular diagnosis of Mycobacterium tuberculosis TB - Second MBBS - Molecular diagnosis of Mycobacterium tuberculosis TB - Second MBBS -
Molecular diagnosis of Mycobacterium tuberculosis TB - Second MBBS -
 
New Generation Sequencing Technologies: an overview
New Generation Sequencing Technologies: an overviewNew Generation Sequencing Technologies: an overview
New Generation Sequencing Technologies: an overview
 
Detection of gm crops
Detection of gm cropsDetection of gm crops
Detection of gm crops
 
MDC Connects: Cell-based screening: Old dogs with new tricks
MDC Connects: Cell-based screening: Old dogs with new tricksMDC Connects: Cell-based screening: Old dogs with new tricks
MDC Connects: Cell-based screening: Old dogs with new tricks
 
RNA Extraction of Peste Des Petits Ruminants Virus (PPRV) from Clinical Sampl...
RNA Extraction of Peste Des Petits Ruminants Virus (PPRV) from Clinical Sampl...RNA Extraction of Peste Des Petits Ruminants Virus (PPRV) from Clinical Sampl...
RNA Extraction of Peste Des Petits Ruminants Virus (PPRV) from Clinical Sampl...
 
PRODUCTION OF SEROTYPE 6-DERIVED RECOMBINANT ADENO-ASSOCIATED VIRUS IN SERUM-...
PRODUCTION OF SEROTYPE 6-DERIVED RECOMBINANT ADENO-ASSOCIATED VIRUS IN SERUM-...PRODUCTION OF SEROTYPE 6-DERIVED RECOMBINANT ADENO-ASSOCIATED VIRUS IN SERUM-...
PRODUCTION OF SEROTYPE 6-DERIVED RECOMBINANT ADENO-ASSOCIATED VIRUS IN SERUM-...
 
6-8-2015 AACC Poster HIV p24 S-PLEX - Stengelin_final
6-8-2015 AACC Poster HIV p24 S-PLEX - Stengelin_final6-8-2015 AACC Poster HIV p24 S-PLEX - Stengelin_final
6-8-2015 AACC Poster HIV p24 S-PLEX - Stengelin_final
 
Grafström - Lush Prize Conference 2014
Grafström - Lush Prize Conference 2014Grafström - Lush Prize Conference 2014
Grafström - Lush Prize Conference 2014
 
A visual chip-based coimmunoprecipitation technique for analysis of protein–p...
A visual chip-based coimmunoprecipitation technique for analysis of protein–p...A visual chip-based coimmunoprecipitation technique for analysis of protein–p...
A visual chip-based coimmunoprecipitation technique for analysis of protein–p...
 
Aacr2009 chip
Aacr2009 chipAacr2009 chip
Aacr2009 chip
 
Protein corona associated with nanoparticles
Protein corona associated with nanoparticlesProtein corona associated with nanoparticles
Protein corona associated with nanoparticles
 
Implementation of histopathological techniques and transmission electron micr...
Implementation of histopathological techniques and transmission electron micr...Implementation of histopathological techniques and transmission electron micr...
Implementation of histopathological techniques and transmission electron micr...
 
Molecular Environmental Microbiology.ppt
Molecular Environmental Microbiology.pptMolecular Environmental Microbiology.ppt
Molecular Environmental Microbiology.ppt
 
microarray_paper
microarray_papermicroarray_paper
microarray_paper
 
Qualify
QualifyQualify
Qualify
 
Pcr array whitepaper_app
Pcr array whitepaper_appPcr array whitepaper_app
Pcr array whitepaper_app
 
LabOnAChip 13_4864
LabOnAChip 13_4864LabOnAChip 13_4864
LabOnAChip 13_4864
 
Microarray validation
Microarray validationMicroarray validation
Microarray validation
 
2013 APCBEES MALAYSIA CONFERENCES
2013 APCBEES MALAYSIA CONFERENCES2013 APCBEES MALAYSIA CONFERENCES
2013 APCBEES MALAYSIA CONFERENCES
 
132 gene expression in atherosclerotic plaques
132 gene expression in atherosclerotic plaques132 gene expression in atherosclerotic plaques
132 gene expression in atherosclerotic plaques
 

Mehr von igorod

Принципы политики инновационного центра «Сколково» в области публичных коммун...
Принципы политики инновационного центра «Сколково» в области публичных коммун...Принципы политики инновационного центра «Сколково» в области публичных коммун...
Принципы политики инновационного центра «Сколково» в области публичных коммун...
igorod
 
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
igorod
 
Клаудмак
КлаудмакКлаудмак
Клаудмак
igorod
 
Базелевс Инновации
Базелевс ИнновацииБазелевс Инновации
Базелевс Инновации
igorod
 
Сателлит Инновация
Сателлит ИнновацияСателлит Инновация
Сателлит Инновация
igorod
 
М-Пауэр Ворлд
М-Пауэр ВорлдМ-Пауэр Ворлд
М-Пауэр Ворлд
igorod
 
ДАТАДВАНС
ДАТАДВАНСДАТАДВАНС
ДАТАДВАНС
igorod
 
Фарма Био
Фарма БиоФарма Био
Фарма Био
igorod
 
Уральский центр биофармацевтических технологий
Уральский центр биофармацевтических технологийУральский центр биофармацевтических технологий
Уральский центр биофармацевтических технологий
igorod
 
НьюВак
НьюВакНьюВак
НьюВак
igorod
 
Команда энергичных предпринимателей
Команда энергичных предпринимателейКоманда энергичных предпринимателей
Команда энергичных предпринимателей
igorod
 
АБИ ИнфоПоиск
АБИ ИнфоПоискАБИ ИнфоПоиск
АБИ ИнфоПоиск
igorod
 
Инноград Пущино
Инноград ПущиноИнноград Пущино
Инноград Пущино
igorod
 
Научно-технический Центр тонкопленочных технологий на основе кремния
Научно-технический Центр тонкопленочных технологий на основе кремнияНаучно-технический Центр тонкопленочных технологий на основе кремния
Научно-технический Центр тонкопленочных технологий на основе кремния
igorod
 
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
igorod
 
CeBIT: Благодарственное письмо В.Ф.Вексельбергу
CeBIT: Благодарственное письмо В.Ф.ВексельбергуCeBIT: Благодарственное письмо В.Ф.Вексельбергу
CeBIT: Благодарственное письмо В.Ф.Вексельбергу
igorod
 
Презентация проекта литий-ионных аккумуляторов
Презентация проекта литий-ионных аккумуляторовПрезентация проекта литий-ионных аккумуляторов
Презентация проекта литий-ионных аккумуляторов
igorod
 
Меморандум о сотрудничестве между Торговым представительством Российской Феде...
Меморандум о сотрудничестве между Торговым представительством Российской Феде...Меморандум о сотрудничестве между Торговым представительством Российской Феде...
Меморандум о сотрудничестве между Торговым представительством Российской Феде...
igorod
 
Технопарк «Сколково»
Технопарк «Сколково»Технопарк «Сколково»
Технопарк «Сколково»
igorod
 

Mehr von igorod (20)

Принципы политики инновационного центра «Сколково» в области публичных коммун...
Принципы политики инновационного центра «Сколково» в области публичных коммун...Принципы политики инновационного центра «Сколково» в области публичных коммун...
Принципы политики инновационного центра «Сколково» в области публичных коммун...
 
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
 
Клаудмак
КлаудмакКлаудмак
Клаудмак
 
Базелевс Инновации
Базелевс ИнновацииБазелевс Инновации
Базелевс Инновации
 
Сателлит Инновация
Сателлит ИнновацияСателлит Инновация
Сателлит Инновация
 
М-Пауэр Ворлд
М-Пауэр ВорлдМ-Пауэр Ворлд
М-Пауэр Ворлд
 
ДАТАДВАНС
ДАТАДВАНСДАТАДВАНС
ДАТАДВАНС
 
Фарма Био
Фарма БиоФарма Био
Фарма Био
 
Уральский центр биофармацевтических технологий
Уральский центр биофармацевтических технологийУральский центр биофармацевтических технологий
Уральский центр биофармацевтических технологий
 
НьюВак
НьюВакНьюВак
НьюВак
 
Команда энергичных предпринимателей
Команда энергичных предпринимателейКоманда энергичных предпринимателей
Команда энергичных предпринимателей
 
АБИ ИнфоПоиск
АБИ ИнфоПоискАБИ ИнфоПоиск
АБИ ИнфоПоиск
 
Инноград Пущино
Инноград ПущиноИнноград Пущино
Инноград Пущино
 
Технопарк «Сколково»
Технопарк «Сколково»Технопарк «Сколково»
Технопарк «Сколково»
 
Научно-технический Центр тонкопленочных технологий на основе кремния
Научно-технический Центр тонкопленочных технологий на основе кремнияНаучно-технический Центр тонкопленочных технологий на основе кремния
Научно-технический Центр тонкопленочных технологий на основе кремния
 
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
 
CeBIT: Благодарственное письмо В.Ф.Вексельбергу
CeBIT: Благодарственное письмо В.Ф.ВексельбергуCeBIT: Благодарственное письмо В.Ф.Вексельбергу
CeBIT: Благодарственное письмо В.Ф.Вексельбергу
 
Презентация проекта литий-ионных аккумуляторов
Презентация проекта литий-ионных аккумуляторовПрезентация проекта литий-ионных аккумуляторов
Презентация проекта литий-ионных аккумуляторов
 
Меморандум о сотрудничестве между Торговым представительством Российской Феде...
Меморандум о сотрудничестве между Торговым представительством Российской Феде...Меморандум о сотрудничестве между Торговым представительством Российской Феде...
Меморандум о сотрудничестве между Торговым представительством Российской Феде...
 
Технопарк «Сколково»
Технопарк «Сколково»Технопарк «Сколково»
Технопарк «Сколково»
 

Archakov A. from human genome project to human proteome project

  • 1. FROM HUMAN GENOME PROJECT TO HUMAN PROTEOME PROJECT /HPP/: RUSSIAN PARTICIPATION ARCHAKOV A.I. INSTITUTE OF BIOMEDICAL CHEMISTRY OF RAMS, MOSCOW, RUSSIA www.ibmc.msk.ru [ HTTP://WWW.PROTEOME.RU/EN/ROADMAP ]
  • 2. GENOME [OUTLINE] TRANSCRIPTOME [LAYOUT] PROTEOME [PRODUCT]
  • 3. THE MAIN DIFFERENCE BETWEEN GENOMICS AND PROTEOMICS: THE SAME GENOME THE DIFFERENT PROTEOME CATERPILLAR BUTTERFLY
  • 4. STEPS OF HPP HUPO FORMATION: BARBADOS CONFERENCE 2007 05/11-01-2007 H. PEARSEN. BIOLOGISTS INITIATE PLAN TO MAP HUMAN PROTEOME. NATURE, 452, 24, 920-921, 2008. HUMAN PROTEOME PROJECT HUPO 2008, 7 th WORLD CONGRESS, 16/20-08-08,Amsterdam, NL HPP MOSCOW WORKSHOP, RUSSIA 20/21-03,2009 SEOUL , KHUPO , 26/27-03-2009 CANADIAN HUPO , TORONTO, 26/ 30 -0 9 -2009
  • 5.
  • 6. HOW MANY PROTEINS EXIST IN HUMAN BODY? 22 PAIRS SOMATIC CHR 1 PAIR SEX CHR ________________________________________________ [1] The sequence of the human genome. Venter et al., Science. 2001 [2] Extent of modifications in Human Proteome Samples…, Nielsen et al., MCP, 2009 [3] Biospecific irreversible fishing… Archakov et al., Proteomics , 2009 HUMAN GENOME 20 000 GENES [1] ~ 5 0 PROTEIN FORMS PER GENE [2] ~ 1 [2] - 2 [3] MLN.PROTEINS
  • 7. HOW MANY PROTEINS IN HUMAN PROTEOME : dependence between detection limit of the staining method and number of proteins spots on 2DE. (Archakov et al., PROTEOMICS (2009), 9, 1326-1343). DL , М 10 - 6 10 - 9 10 - 8 10 - 7 10 -20 10 -24 10 100 1000 500 2000 380 Thsnd Silver Tio Silver Glutar Cy5 Cy5Sat AmidoBlack Number of protein species Coummassi Blue HEP G2 CELLS BLOOD PLASMA Staining Methods: 2.2 Mln 10 - 10 10 -1 1 10 -1 2 10 -1 3 3000 4000 5000
  • 8.  
  • 9.  
  • 10.
  • 11.
  • 12. CHROMOSOME STATISTICS Ensembl release 60 - Nov 2010 http://www.ensembl.org LENGTH (BPS): 78,077,248 GENES 513 KNOWN PROTEIN-CODING GENES: 285 PSEUDOGENE GENES: 64 miRNA Genes: 32 rRNA Genes: 13 snRNA Genes: 51 snoRNA Genes: 36 Misc RNA Genes: 25
  • 13. DATA MINING STATISTICS FOR 18 th CHROMOSOME: 286 MASTER PROTEIN CODING GENES PRIDE = 224 identified proteins Protein Atlas = 102 proteins In PRIDE only In PRIDE and in Protein Atlas In Protein Atlas only 48 PROTEINS – NOT CONFIRMED ( 1 2) (13 4 ) (90)
  • 14. How many proteins can we expect for 18 th chromosome ? 28 5 Trancriptome analisys of 18 th chromosome Over 80% of the genes undergo alternative splicing (Kampa at. al, Genome Res., 2004, 14, 331-342) + 230 516 On average, each of them can have 50 PTMs (Nielsen M, Savitski M, Zubarev R, MCP, 2006, 5, 2384-) x 50 25800 Protein species can be expected as expressed in HepG2 cell line
  • 15. http://www.proteome.ru/en/roadmap/ http://www.hupo.org/research/hpp/soc/ ROADMAP PROTEOME OF THE 18-TH HUMAN CHROMOSOME: GENE CENTRIC IDENTIFICATION OF TRANSCRIPTS, PROTEINS AND PEPTIDES
  • 16. RusHPP CONSISTS OF TWO PHASES: GOAL OF THE PILOT PHASE IS IDENTIFICATION OF ALL MASTER PROTEINS PRODUCED BY 18thCHR IN LIVER AND HEP2G CELLS AND IDENTIFICATION OF THEM IN PLASMA WITH SENSITIVITY 10 -18 M ( 1 PROTEIN COPY/µL ) AND 1 PROTEIN COPY PER 10 3 LIVER OR HEP2G CELLS.
  • 17.
  • 18. PRINCIPLE DIFFERENCE BETWEEN GENOMIC AND PROTEOMICS PRINCIPLE DIFFERENCE BETWEEN GENOMIC AND PROTEOMICS IS EXISTENCE OF POLYMERASE CHAIN REACTION (PCR) IN GENOMICS ALLOWING TO MULTIPLY NUCLEIC ACID MOLECULES AND ABSENCE OF PCR-LIKE REACTION IN PROTEOMICS. DUE TO PCR GENOMICS DOES NOT HAVE DETECTION LIMIT (DL ) OBSTACLE. PROTEOMICS HAS IT.
  • 19.
  • 20. WHAT IS REVERSE AVOGADRO’s NUMBER ? N A = 6.022x10 23 MOLECULES/MOLE 1 MOLE - 1L - 1M 1/N A ≈10 -24 MOLE/MOLECULE ≈1MOLECULE/L = 10 -24 M [Archakov A.I. et. al. PROTEOMICS 2007, 7, 4–9 ]
  • 21.
  • 22. COMBINING OF IRREVERSIBLE FISHING TECHNOLOGY WITH AFM
  • 23.
  • 24. EXPERIMENT SUCCINIMIDE MODIFIED MICA С AVIDIN =10 -13 M ; V=1 ml; T=37 0 C; t INCUB = 60 min S ACTIVATION =0,4 mm 2 ; S scan =16FRAMES*25  m 2 =4*10 -4 mm 2 t SCAN =240min N MOLECULES =5122  500 molecules /400  m 2 AFM IRREVERSIBLE CHEMICAL FISHING C VS =5 *10 - 6 M (FROM EXPERIMENT) C VS = 10 - 5 M (FROM THEORY) AVIDIN ON AFM-SUPPORT 5nm 5µm 0
  • 25.
  • 26. COMBINING OF IRREVERSIBLE FISHING WITH MRM MS
  • 27. Experimental workflow for low and ultra low copied protein detection QqQ dynamic MRM analysis of individual proteins and in Human Plasma Step 1 Step 2 Step 3 HPLC-Chip Q-TOF (Agilent 6510) HPLC-Chip QqQ (Agilent 6410)
  • 28. MRM STRATEGY FOR LOW AND ULTRA-LOW COPIED PROTEIN DETECTION (BSA and CYP102/BM3/ as an example) Detection limit for purified proteins is 10 -16 M, 600 copies/1  l (s/n>7) Detection limit for CYP102 in the presence of human serum is 10 -14 M 60 000 copies/1  l (s/n>7) +serum + trypsin + trypsin
  • 29. IRREVERSIBLE BINDING OF PROTEINS ON BrCN-SEPHAROSE BEADS 0.5-50 ml PURIFIED CYP102/BSA IN THE PRESENCE OF HUMAN SERUM IRREVERSIBLE BINDING OF PROTEINS ON BrCN-SEPHAROSE BEADS FOLLOWING BY DIGESTION WITH TRYPSIN DETECTION LIMIT FOR CYP102/BSA FOR PURIFIED PROTEIN AND PROTEINS IN THE PRESENCE OF HUMAN SERUM IS 10 -18 M, 1 COPY/1µL 10E-9M 10E-12M 10E-15M 10E-18M
  • 30.
  • 31.
  • 32. DETECTION OF HCVcoreAg AT TWO SPOTS AFM CHIP FROM HCVcoreAg SOLUTION (C=10 -9 М ) ANTI-HBsAg imm (CONTROL SPOT) 1 2 3 4 1 – ANTI HCVcoreAg 2 – anti-HCVcore imm /HCVcoreAg h= 3-7 nm 3 – ANTI-HBsAg imm 4 – AFM CHIP AFTER INCUBATION IN HCVcore Ag (C=10 -9 М ) SOLUTION SURFACE TOPOGRAPHY HAS NOT CHANGED ANTI-HCVcoreAg imm SPOT
  • 33. HCVcoreAg HBsAg COINCIDENCE – 76% COINCIDENCE – 8 9 % COMPARISON OF AFM AND OTHER METHODS (ELISA AND PCR) FOR DETECTION OF HBsAg AND HCVcoreAg 132 aa of 191 (70%) in HCVcore PROTEIN SEQUENCE ARE INVARIANT [Bukh et.al., PNAS, 1994, 91, 8239-8234 ] POSSIBLE REASON OF DISAGREEMENT : 183 aa of 226 (80%) in HBsAg PROTEIN SEQUENCE ARE INVARIANT [Norder et.al., J. Gener. Virol.,, 1992, 73, 1201-1208 ] PCR (RNA HCV) А FM + - + 24 2 - 8 7 ELISA AFM + - + 25 3 - 1 6
  • 34. PROTEOTYPE IS A RESULT OF: NEW DIAGNOSTIC TESTS BASED ON PROTEOTYPING
  • 35.
  • 36. (A) AFM IMAGES OF PHOSPHOLIPID NANOPARTICLES ON THE MICA SURFACE (A) AND DISTRIBUTION OF PARTICLES BY SIZE (B) (B)
  • 37.
  • 38.